Skip to main content

Belantamab Mafodotin-blmf

Placeholder slot
 (beh-LAN-tuh-mab MA-foh-DOH-tin)

This page contains brief information about belantamab mafodotin-blmf and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Belantamab mafodotin-blmf is approved to treat:

Belantamab mafodotin-blmf is only available as part of a special program called Blenrep REMS (Risk Evaluation and Mitigation Strategies).

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that belantamab mafodotin-blmf provides a clinical benefit in these patients.

More About Belantamab Mafodotin-blmf

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Belantamab Mafodotin-blmf - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Cancer Therapies

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Belantamab Mafodotin-blmf - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: